List All Colorectal Cancer Trials

Colorectal Cancer

 

TheraSphere® Metastatic Colorectal Carcinoma of the Liver (7627 - TS-102)
A Phase III Clinical Trial Evaluating TheraSphere® in Patients with Metastatic Colorectal Carcinoma of the Liver Who Have Failed First Line Chemotherapy

Investigator: William Harris;   Conditions: Colorectal Cancer;    Status: Recruiting;   Study ID: NCT01483027

MDX-1105 for Advanced or Recurrent Cancer (UW08038)
A Phase 1, Open-label, Dose-escalation, Multidose Study of MDX-1105 Administered Every 14 Days in Subjects With Selected Advanced or Recurrent Solid Tumors

Investigator: Scott S. Tykodi, MD, PhD;   Conditions: Renal Cell Carcinoma, Non-small Cell Lung Cancer, Malignant Melanoma, Epithelial Ovarian Cancer;    Status: Closed;   Study ID: NCT00729664

Molecular Markers for Colon Cancer Screening
Validation and Comparison of Biomarkers for the Early Detection of Colorectal Adenocarcinoma

Investigator: William M. Grady, MD;   Conditions: Colon Cancer, Rectal Cancer;    Status: Recruiting;   Study ID: NCT01511653

Chemotherapy or Chemotherapy + Radiation for Rectal Cancer Patients Undergoing Surgery (The PROSPECT Trial-N1048)
A Phase II/III Trial of Neoadjuvant FOLFOX, With Selective Use of Combined Modality Chemoradiation Versus Preoperative Combined Modality Chemoradiation for Locally Advanced Rectal Cancer Patients Undergoing Low Anterior Resection With Total Mesorectal Excision

Investigator: Gabriela Chiorean, MD;   Conditions: Colorectal Cancer;    Status: Recruiting;   Study ID: NCT01515787

FOLFOXIRI/Avastin Versus FOLFOX/Avastin for Metastatic Colorectal Cancer-STEAM (13010)
STEAM: (Sequential Triplet And Avastin Maintenance): Folfoxiri/Bevacizumab Regimens (Concurrent And Sequential) Vs. Folfox/Bevacizumab In First-Line Metastatic Colorectal Cancer

Investigator: Gabriela Chiorean, MD;   Conditions: Colorectal Cancer;    Status: Recruiting;   Study ID: NCT01765582

Xilonix in Patients With Advanced Colorectal Cancer
Phase III Double-blinded, Placebo Controlled Study of Xilonix™ (MABp1) for Improving Survival in Metastatic Colorectal Cancer

Investigator: Andrew L. Coveler, MD;   Conditions: Metastatic Colorectal Cancer;    Status: Recruiting;   Study ID: NCT01767857

FOLFOX w/wo Celecoxib for Resected Stage III Colon Cancer (CALGB 80702)
A Phase III Trial of 6 Versus 12 Treatments of Adjuvant FOLFOX Plus Celecoxib or Placebo for Patients With Resected Stage III Colon Cancer

Investigator: Saul E. Rivkin, MD;   Conditions: Colorectal Cancer;    Status: Recruiting;   Study ID: NCT01150045

Chemoradiation Plus Induction or Consolidation Chemotherapy and Total Mesorectal Excision or Non-operative Management for Rectal Cancer (9240)
A Phase II Multicenter Randomized Trial Evaluating 3-year Disease-Free Survival in Patients with Locally Advanced Rectal Cancer treated with Chemoradiation plus Induction or Consolidation Chemotherapy, and Total Mesorectal Excision or Non-Operative Management

Investigator: Andrew Coveler, MD;   Conditions: Rectal Cancer; Locally Advanced Rectal Cancer (LARC);    Status: Recruiting;   Study ID: NCT02008656